We read with interest the article by Woolley et al. presenting three cases of immigrants to Australia living with HIV/AIDS and experiencing loss of adherence to their antiretroviral therapy (ART) while visiting friends and relatives in their native countries. 1 Indeed, adherence remains a challenge in such patients experiencing high geographical mobility, stigma and discrimination. 2, 3 To explore adherence related to geographical mobility in such patients, 268 native sub-Saharan African individuals living in France and having a virologically (pVL < 200 copies/ml) controlled HIV infection on stable ART were enrolled during the 8-week period before a planned trip to a sub-Saharan country lasting for between two weeks and six months in 2006-2009. Self-administered questionnaires, previously validated among migrants in France, 4 administered at enrolment and during the week following the return to France, collected information about adherence to ART in the 4 days and 4 weeks preceding enrolment while in France or the day back to France while travelling.
Adherence failure was defined as switching from adherence (high or moderate, i.e. 80-100% of prescribed tablets taken) to non-adherence (<80%) in the 200 patients adherent to ART at enrolment who completed the questionnaire at the post-travel visit. Risk factors for adherence failure were assessed by using a multivariable logistic regression model including variables associated with adherence failure in the univariate model (p < 0.20). Social status (literacy level, employment, type of housing and marital status), perception about treatment efficacy and toxicity, HIV status disclosure and variables related to the travel: locations visited (urban/rural), period of travelling (during the Ramadan fasting period and respecting the fast, or not), use of traditional medicine, illness leading to a medical consultation, unexpected traumatic events and trip extension were considered for the analysis.
Eighty-two patients were men (41%) and median age was 41 years. Median CD4 count was 430 cells/mm 3 and 60 patients (30%) had AIDS. Median duration on ART was 3 years. Socioeconomic conditions were comparable to those reported in this population as 90 patients (45%) Adherence failure: decrease in adherence rate from being adherent (adherence 80-100%) -to being non-adherent (adherence <80%). b Troubles included political, natural, accidental (road injury, theft) and familial (bereavement, constraints, conflicts). cART, combination antiretroviral therapy; OR, odds ratio.
had reached at least the secondary school, 118 (59%) were employed, 139 (69%) reported being owners or renters of their home. 5 HIV status disclosure (to patients' partners, parents, other family members and/or friends) in France and/or in their native country was 85%.
The median (IQR) duration of the trip was 6 (4-9) weeks; its main purpose was to meet the family. Twenty-three patients (11%) experienced adherence failure. After adjustment on type of housing, singlehood and ART effectiveness perception, HIV status disclosure was associated with a 81% lower likelihood, and unexpected traumatic events and prolongation of the stay with a 7.8 and 5.3 times higher likelihood of non-adherence, respectively (Table 1) .
Despite having stabilized social and HIV status, our target migrant population could have to face additional barriers to adherence when travelling, further compromising the virological response durability. 6 These patients should thus receive tailored counselling before the travel. In particular, any extension of the stay should be anticipated by ensuring that they travel with more medications than initially required by the planned duration of the trip. Disclosure of HIV diagnosis should be encouraged as it is associated with higher levels of social support.
